GSK plc (LON:GSK – Get Free Report) announced a dividend on Wednesday, July 31st, Upcoming.Co.Uk reports. Shareholders of record on Thursday, August 15th will be given a dividend of GBX 15 ($0.19) per share on Thursday, October 10th. This represents a yield of 0.97%. The ex-dividend date is Thursday, August 15th. The official announcement can be seen at this link.
GSK Stock Down 2.0 %
Shares of LON GSK opened at GBX 1,512 ($19.45) on Wednesday. The company’s 50 day moving average price is GBX 1,591.83 and its 200-day moving average price is GBX 1,637.09. The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87. GSK has a 52-week low of GBX 1,330.19 ($17.11) and a 52-week high of GBX 1,823.50 ($23.46). The company has a market capitalization of £61.69 billion, a P/E ratio of 1,415.14, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27.
Analysts Set New Price Targets
Several research firms recently issued reports on GSK. Citigroup dropped their target price on shares of GSK from GBX 2,120 ($27.27) to GBX 1,900 ($24.44) and set a “buy” rating on the stock in a report on Friday, July 5th. Barclays restated an “equal weight” rating and set a GBX 1,725 ($22.19) target price on shares of GSK in a research report on Tuesday, May 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($27.01) target price on shares of GSK in a research note on Thursday, June 27th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Monday. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,820 ($23.41).
Insider Buying and Selling
In other GSK news, insider Wendy Becker purchased 446 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was acquired at an average price of GBX 1,614 ($20.76) per share, for a total transaction of £7,198.44 ($9,259.63). 1.60% of the stock is owned by company insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
- Five stocks we like better than GSK
- What Investors Need to Know About Upcoming IPOs
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.